Spots Global Cancer Trial Database for Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Official Title: Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study

Study ID: NCT00929669

Conditions

Gonadotroph Adenomas

Interventions

pasireotide LAR

Study Description

Brief Summary: The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

Detailed Description: Gonadotroph adenomas are the most common pituitary macroadenomas. Currently no medical treatment as been found that decreases the size of these adenomas, so surgery is the only treatment. The reason to think that pasireotide might affect gonadotroph adenomas is that pasireotide binds avidly to somatostatin subtype 5 receptors, and gonadotroph adenomas express these receptors. For this study, three subjects who have gonadotroph adenomas, as judged by a macroadenoma of the pituitary and elevated serum FSH concentration, will be treated with a long-acting form of pasireotide once a month for one year. The effect of pasireotide on the size of the adenoma will be determined by MRI, and FSH secretion will be judged by the serum concentration.